Diagnostic Tools for Endometriosis in Poland: A Comparative Assessment of Reliability and Out-of-Pocket Costs.
Objectives: This study aimed to assess the availability, diagnostic reliability, and out-of-pocket costs of endometriosis diagnostic tools available on the private healthcare market in Poland. Methods: A desk-based analysis was …
MAIPL THERAPEUTICS, INC. FORMS STRATEGIC ALLIANCE WITH ENDOSURE, INC. TO FACILITATE FIRST‑IN‑HUMAN TRIAL OF NOVEL NON‑HORMONAL ENDOMETRIOSIS THERAPY - BioSpace
MAIPL THERAPEUTICS, INC. FORMS STRATEGIC ALLIANCE WITH ENDOSURE, INC. TO FACILITATE FIRST‑IN‑HUMAN TRIAL OF NOVEL NON‑HORMONAL ENDOMETRIOSIS THERAPY BioSpace
MAIPL THERAPEUTICS, INC. FORMS STRATEGIC ALLIANCE WITH ENDOSURE, INC. TO FACILITATE FIRST‑IN‑HUMAN TRIAL OF NOVEL NON‑HORMONAL ENDOMETRIOSIS THERAPY - PR Newswire
MAIPL THERAPEUTICS, INC. FORMS STRATEGIC ALLIANCE WITH ENDOSURE, INC. TO FACILITATE FIRST‑IN‑HUMAN TRIAL OF NOVEL NON‑HORMONAL ENDOMETRIOSIS THERAPY PR Newswire
MAIPL THERAPEUTICS, INC. FORMS STRATEGIC ALLIANCE WITH ENDOSURE, INC. TO FACILITATE FIRST‑IN‑HUMAN TRIAL OF NOVEL NON‑HORMONAL ENDOMETRIOSIS THERAPY - Yahoo Finance
MAIPL THERAPEUTICS, INC. FORMS STRATEGIC ALLIANCE WITH ENDOSURE, INC. TO FACILITATE FIRST‑IN‑HUMAN TRIAL OF NOVEL NON‑HORMONAL ENDOMETRIOSIS THERAPY Yahoo Finance
Safety and pharmacology of AMY109, a long-acting anti-interleukin-8 antibody, for endometriosis: a double-blind, randomized phase 1 trial.
To evaluate the safety and pharmacokinetics/pharmacodynamics of AMY109, an anti-interleukin-8 recycling antibody in a first-in-human phase 1 trial in healthy volunteers (HVs) and patients with endometriosis.